clinical research prime

Senior Stomach Bug 60+

  • A Phase 3study to evaluate the safety and efficacy of mRNA-1403 vaccine in the prevention of Norovirus Acute Gastroenteritis in adults 60+ .
  • Participants will receive study-related treatment at no cost and will be compensated for time and travel.

Eligible participants must meet following criteria:

  • Adult 60+

  • Does not have chronic GI symptoms/diagnosis that would be confused with acute gastroenteritis